PressMay 9, 2024 Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
PressMay 8, 2024 Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
PressMay 8, 2024 Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
PressMay 8, 2024 Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
PressMay 6, 2024 MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
PressMay 6, 2024 Lophos Pharmaceuticals Corp. Enters Into Letter of Intent to Acquire the Assets of Magicactus.com
PressMay 3, 2024 MindBio Therapeutics Scientists Present Landmark Women’s Health Trials, Company to Release Phase 2A Depression Trial Secondary Data This Month
PressMay 3, 2024 PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
PressMay 3, 2024 Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
PressMay 3, 2024 Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
PressMay 2, 2024 PharmaDrug’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
PressApril 30, 2024 Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
PressApril 30, 2024 FSD Pharma Inc. Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd
PressApril 29, 2024 Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
PressApril 29, 2024 Lophos Pharmaceuticals Corp. Expands Peyote Cultivation with the Successful Planting of 3,000 Seeds
